Soluble TNFRp75 regulates host protective immunity against *Mycobacterium tuberculosis*

Roanne Keeton,1 Nasiema Allie,1 Ivy Dambuza,1 Brian Abel,1,2 Nai-Jen Hsu,1 Boipelo Sebesho,1 Philippa Randall,1 Patricia Burger,1 Elizabeth Fick,1 Valerie F.J. Quesniaux,3 Bernhard Ryffel,3 and Muazzam Jacobs1,4

1Division of Immunology, Department of Clinical Laboratory Sciences and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 2Singapore Immunology Network, Agency for Science, Technology and Research, Singapore. 3University of Orleans and CNRS UMR7355, Experimental and Molecular Immunology and Neurogenetics, Orleans, France. 4National Health Laboratory Service, Johannesburg, South Africa.

Development of host protective immunity against *Mycobacterium tuberculosis* infection is critically dependent on the inflammatory cytokine TNF. TNF signals through 2 receptors, TNFRp55 and TNFRp75; however, the role of TNFRp75-dependent signaling in immune regulation is poorly defined. Here we found that mice lacking TNFRp75 exhibit greater control of *M. tuberculosis* infection compared with WT mice. TNFRp75−/− mice developed effective bactericidal granulomas and demonstrated increased pulmonary recruitment of activated DCs. Moreover, IL-12p40-dependent migration of DCs to lung draining LNs of infected TNFRp75−/− mice was substantially higher than that observed in WT *M. tuberculosis*-infected animals and was associated with enhanced frequencies of activated *M. tuberculosis*-specific IFN-γ-expressing CD4+ T cells. In WT mice, TNFRp75 shedding correlated with markedly reduced bioactive TNF levels and IL-12p40 expression. Neutralization of TNFRp75 in *M. tuberculosis*-infected WT BM-derived DCs (BMDCs) increased production of bioactive TNF and IL-12p40 to a level equivalent to that produced by TNFRp75−/− BMDCs. Addition of exogenous TNFRp75 to TNFRp75−/− BMDCs infected with *M. tuberculosis* decreased IL-12p40 synthesis, demonstrating that TNFRp75 shedding regulates DC activation. These data indicate that TNFRp75 shedding downmodulates protective immune function and reduces host resistance and survival; therefore, targeting TNFRp75 may be beneficial for improving disease outcome.

Introduction

*Mycobacterium tuberculosis* is a highly efficient intracellular pathogen that requires specific cellular adaptive Th1 immune responses for host protection. Successful control of *M. tuberculosis* relies not only on a complex but organized series of interactions among mycobacteria, antigen-presenting cells, and lymphocytes, but also on the coordinated production of chemokines and cytokines. Although redundancy has been illustrated for many cytokines, others such as TNF, IL-1, IL-12, and IFN-γ cannot be functionally replaced, and the absence of any of these proves lethal during *M. tuberculosis* challenge. TNF and its corresponding receptors (TNFRs), TNFRp55 and TNFRp75 (encoded by TNFRSF1A and TNFRSF1B, respectively), are members of supergene families (1). TNF-mediated signaling has a significant influence on the outcome of several infectious diseases and contributes to protective immunity against fungal, viral, protozoan, and bacterial pathogens (2). TNF is synthesized as a membrane-bound protein that is cleaved to a soluble form by TNF converting enzyme (TACE) (3). Both forms of the ligand are bioactive and can signal as homorimers through either of the receptors, although membrane-bound TNF is thought to preferentially signal through TNFRp75, and soluble TNF is partitioned to TNFRp55 (4). TNFRp55 and TNFRp75 show structural similarity with respect to 4 cysteine-rich motifs found in their extracellular regions, but lack structural compatibility in their cytoplasmic domains (1, 4); consequently, post-binding events and cellular responses are different for each TNFR (5). Moreover, both TNFRp55 and TNFRp75 can be maintained either as a membrane-bound form or can be shed from the cell surface. The effect of shedding and its impact on bioactive ligand availability is controversial. Evidence proposing an antagonistic effect, where ligand signaling is inhibited, has been published (6, 7). Conversely, it was suggested that ligand interaction with soluble receptor may act agonistically, by enhancing the half-life of the ligand and hence increasing its bioavailability (8).

TNF deficiency has profound effects on protective immunity against *M. tuberculosis* (9–13), even though the homolog, lympho-toxin α (LTo), is able to signal through the same receptors (2). The role of TNF in protective immunity against mycobacterial infection has been extensively investigated using mice deficient for TNF signaling (9, 10, 13, 14) or by neutralization studies (11, 12). The more recent generation of mouse strains expressing only the membrane form of TNF has allowed for the investigation of the respective roles of soluble and membrane-bound TNF in host immune function during mycobacterial challenge (15–23).

TNF is important for the cell recruitment required in order to form granulomas that restrict bacilli replication and prevent bacterial dissemination (13, 24–26). The establishment and continued maintenance of the structural integrity of granulomas are key for host protection, as illustrated in gene-targeted mice that are defective for granuloma formation. Such animals are unable to control bacilli replication, resulting in bacterial dissemination and premature death after infection with either virulent or avirulent mycobacterial species (9–11, 13, 27). Nonetheless, excessive TNF has deleterious effects and is considered to significantly influence degradation of lung tissue through promoting severe inflammation (14, 28) and to aid in bacterial replication in alveolar macrophages (29).
The role of TNFRp55 signaling in the host protective immune response to mycobacterial infections has been addressed in various mycobacterial infection models, including intravenous \( M. \) \textit{tuberculosis} infection (24) and intraperitoneal \( M. \) \textit{bovis} 
Calmette-Guerin (BCG) infection (26), in which TNFRp55 deficiency results in premature death. Mortality of TNFRp55-deficient mice during intravenous \( M. \) \textit{avium} challenge was characterized by excessive T cell infiltration and was associated with IL-12-dependent disintegration of granulomatous lesions (30). Similar to TNF-deficient mice, TNFRp55-deficient mice displayed defective granuloma formation in response to \( M. \) \textit{bovis} BCG infection, and treatment with anti-TNF mAb resulted in the regression of fully established granulomas in both TNF- and TNFRp55-deficient mice (11, 26). The similarity in phenotype between TNF- and TNFRp55-deficient mice suggests that TNFRp55 signaling is the major conduit for TNF-mediated immune function against mycobacterial infections. The role of TNFRp75 in host immune function during pathogen challenge, however, is controversial. Previous studies reported a protective role for TNFRp75 against \( H. \) \textit{capsulatum} infection, in which TNFRp75 deficiency resulted in reduced IFN-\( \gamma \) production and premature mortality (31). In contrast, TNFRp75 was redundant for protection against \( L. \) \textit{monocytogenes}, while it had a similarly limited role in immune responses against \( M. \) \textit{bovis} BCG (32, 33). Furthermore, in challenge studies with \( P. \) \textit{falciparum}, TNFRp75 inhibited protective immune function (34).

To our knowledge, the role of TNFRp75 in virulent \( M. \) \textit{tuberculosis} infection has not previously been reported, and whether it promotes or inhibits the protective immune response is still contentious. In the present study, we investigated the respective functions of TNFRp55 and TNFRp75 in protective immunity against \( M. \) \textit{tuberculosis} in an aerosol inhalation infection model and explored the mechanisms associated with the increased resistance of TNFRp75-deficient mice to \( M. \) \textit{tuberculosis} infection.

Results

\textit{TNFRp75-deficient mice are resistant to acute \( M. \) \textit{tuberculosis} infection.}

We compared tuberculosis disease progression in WT, \textit{Tnfrsf1a}--/-- (referred to herein as TNFRp55--/--), \textit{Tnfrsf1b}--/-- (TNFRp75--/--), and double-deficient TNFRp55/75--/-- mice upon aerosol infection with \( M. \) \textit{tuberculosis} H37Rv at a dose of 50–100 CFU/lung. We recorded survival for the duration of the study and measured weight loss as a clinical correlate of disease progression (Figure 1, A and B). Similar to previous reports of intravenous \( M. \) \textit{tuberculosis} infection of TNFRp55--/-- mice (24), both TNFRp55--/-- and TNFRp55/75--/-- mouse strains were highly susceptible to infection, lost significant body weight (≥25% of original body weight), and rapidly succumbed to disease (Figure 1, A and B). A small but consistently higher mortality rate was observed in TNFRp55/75--/-- compared with TNFRp55--/-- mice (Figure 1A). Conversely, like WT mice, TNFRp75--/-- mice were resistant to infection, maintained their body weight, and survived the duration of the experiment (Figure 1, A and B). Therefore, TNFRp55 is critical for protection against \( M. \) \textit{tuberculosis} infection, whereas the absence of TNFRp75 did not impair the host response.

We next investigated control of bacilli replication in the mutant strains after \( M. \) \textit{tuberculosis} infection. Whereas the WT, TNFRp55--/--, and TNFRp55/75--/-- strains had comparable pulmonary bacilli burdens up to day 21 after infection, a significantly lower bacilli burden was found in TNFRp55--/-- mice (Figure 1C), suggesting improved control of bacilli growth in the absence of TNFRp75. The kinetics of bacilli replication reflected increasing bacilli levels in all strains until day 21 after infection, after which replication was controlled in WT mice, which reached significance relative to WT values at 28, 35, and 40 days after infection (\( P < 0.01 \); Figure 1C). Furthermore, the absence of both TNFRs rendered mice more susceptible, with significantly higher bacilli burdens recorded in TNFRp55/75--/-- versus TNFRp55--/-- mice at 28, 35, and 40 days after infection (\( P < 0.05 \); Fig-
A striking and unexpected observation was the maintenance of a significantly lower pulmonary bacilli burden in TNFRp75–/– versus WT mice at each time point tested ($P < 0.01$; Figure 1C). Similarly reduced bacilli burdens were also observed at extrapulmonary sites in TNFRp75–/– mice during chronic infection (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI45005DS1). This enhanced bacilli control suggested that TNFRp75 may have an adverse role in host protective immune responses against pulmonary \textit{M. tuberculosis} infection.

TNFRp75 expression has a limited effect on \textit{M. tuberculosis}–induced granuloma formation. Granuloma formation is dependent on signaling of TNF through TNFRp55 in response to \textit{M. tuberculosis} challenge (9); the role of TNFRp75 in this process is undefined. We therefore investigated the effect of TNFRp75 on pulmonary induced pathology: first macroscopically to analyze gross effects, then at a microscopic level to assess cellular responses. Small but distinct lesions were observed on the pleura of WT mice, whereas TNFRp55–/– and TNFRp55/75–/– mice displayed notably enlarged pulmonary lesions at day 35 after infection, with the most severe phenotype evident in TNFRp55/75–/– mice (Figure 2A). In contrast, limited lesion formation was visible in pleura of TNFRp75–/– mice. We next measured lung weight as a surrogate marker of inflammation and found similar weights in all mouse strains until 21 days after infection (Figure 2B). However, in the absence of complete TNFR signaling, TNFRp55/75–/– mice developed an early, uncontrolled inflammatory response, with significantly higher lung weights already evident at 28 days after infection compared with any other strain ($P < 0.01$; Figure 2B), an effect that was sustained for the duration of the study. Lung inflammation in TNFRp55–/– mice was delayed relative to TNFRp55/75–/– mice, but significantly higher lung weights compared with WT mice were nevertheless measured at 40 days after infection ($P < 0.01$; Figure 2B). In contrast, inflammation in TNFRp75–/– mice was significantly lower than their WT counterparts at 28, 35, and 40 days after infection ($P < 0.01$; Figure 2B). The observed differences in inflammation were verified by comparative measurements of the total number of lung cells in infected mice at 35 days after infection (Figure 2C).
compared development at 14, 28, and 35 days after *M. tuberculosis* infection. Lung morphology was largely indistinguishable at 14 days after infection, characterized by intact alveoli and clear bronchi in all strains (data not shown). However, a clear distinction in granuloma structural organization was evident at days 28 and 35 after infection between mice that expressed TNFRp55 and mice in which the receptor was absent (Figure 2, D–K). We observed clearly demarcated granuloma structures, consisting of epithelioid macrophages interspersed with lymphocytes, in WT and TNFRp75–/– mice; conversely, TNFRp55–/– and TNFRp55/75–/– mice were devoid of such organized structures and had noticeable areas of necrosis. Interestingly, granulomas of TNFRp75–/– mice appeared to be smaller than those generated by WT mice (Figure 2, D, E, H, and I). Therefore, our data support a regulatory role for TNFRp55 in the control of pulmonary inflammation and granuloma formation and a dual role for TNFRp75: mediating exacerbation of pulmonary inflammation in the presence of TNFRp55, while enhancing control of inflammation in its absence.

Enhanced protective immunity is maintained, and survival of TNFRp75–/– mice is increased, during chronic *M. tuberculosis* infection. We next assessed whether the enhanced protective phenotype we observed in the absence of TNFRp75 translates to improved outcome during chronic *M. tuberculosis* infection. WT and TNFR75–/– mice were infected with *M. tuberculosis*, and pulmonary bacilli burdens were determined and mortality recorded. Survival of TNFRp75–/– mice was significantly longer than that of their WT counterparts, a result that was associated with significantly lower bacilli levels at 2, 4.5, and 7.5 months after infection (Figure 3, A and B). The reduced pulmonary bacilli burdens in TNFRp75–/– lungs were confirmed visually by Ziehl-Neelsen staining of tissue sections (Figure 3C). Finally, increased inflammation was verified by quantification of...
free alveolar space at 4.5 months after infection, which showed a significant increase in occlusion in WT versus TNFRp75–/– mice ($P < 0.05$; Figure 3D). This was confirmed by analysis of lung tissue sections: pathology was characterized by higher cellular infiltration in WT versus TNFRp75–/– mice at both 4.5 and 7.5 months after infection (Figure 3E). Therefore, the early protection observed during acute infection in TNFRp75–/– mice translated to an enhanced protective outcome of disease.

Increased pulmonary recruitment of activated DCs in TNFRp75–/– mice during M. tuberculosis infection. To understand the immune mechanisms associated with the increased protection observed in M. tuberculosis–infected TNFRp75–/– mice, we asked whether TNFRp75 regulates immune function through recruitment and/or activation of antigen-presenting cells. WT and TNFRp75–/– mice were infected with M. tuberculosis, and DCs (CD11b+CD11c+) were evaluated after 7, 14, and 21 days in the lungs, and cellular activation was assessed by expression of CD80, CD86, and MHCII (Figure 4, A–E). The total number of CD11c+ cells (B), CD11c+MHCII+ (C), CD11c+CD80+ (D), and CD11c+CD86+ (E) cells was assessed by flow cytometry. Data (mean ± SEM of 4 mice per group) are representative of 1 of 2 similar experiments. *$P < 0.05$, **$P < 0.01$, ANOVA.

**Figure 4**
Increased recruitment of activated DCs to the lungs of M. tuberculosis–infected TNFRp75–/– mice. WT and TNFRp75–/– mice were infected at 50–100 CFU with M. tuberculosis. Lungs were harvested at 7, 14, and 21 days after infection, and CD11b+ versus CD11c+ cell distribution (A) and total number of CD11c+ (B), CD11c+MHCII+ (C), CD11c+CD80+ (D), and CD11c+CD86+ (E) cells was assessed by flow cytometry. Data (mean ± SEM of 4 mice per group) are representative of 1 of 2 similar experiments. *$P < 0.05$, **$P < 0.01$, ANOVA.
Enhanced IL-12p40–dependent DC migration is associated with increased recruitment of activated T cells and superior M. tuberculosis–specific Th1 responses in TNFRp75−/− mice. (A) BMDCs from WT and TNFRp75−/− mice were infected at an MOI of 5:1 with M. tuberculosis, and IL-12p40 expression in culture supernatants was analyzed by ELISA. (B–E) WT and TNFRp75−/− mice were infected at 50–100 CFU with M. tuberculosis, and lungs and LNs were harvested 14 and 21 days after infection. The total number of LN CD11c+ cells (B), CD11c+CD86+ cells (C), CD11c+MHCII+ cells (D), and CD4+CD44+ T cells (E) was analyzed by flow cytometry. Data (mean ± SEM of 4 mice per group) are representative of 3 similar experiments. (F) IFN-γ expression by CD4+ T cells in isolated pulmonary cell cultures restimulated with ESAT6 or M. tuberculosis H37Rv (M.tb). Data (mean ± SEM of triplicate values of pooled samples from 4 mice) are representative of 3 similar experiments. *P < 0.05, **P < 0.01, ANOVA.
specific immune response. We first compared CD4+ and CD8+ T cell recruitment and activation in the LNs, postulating that the increased number of activated DCs would lead to increased T cell recruitment and activation in the absence of TNFRp75. Quantification of CD4+CD44+ T cells revealed an early increase in recruitment of activated T cells in the TNFRp75 −/− LNs (Figure 5E). Similarly, the percentage of CD8+CD44+ T cells was increased in TNFRp75−/− compared with WT mice at day 21 (data not shown).

We next evaluated antigen-specific IFN-γ-expressing CD4+ T cells at the sites of infection ex vivo. Low frequencies of IFN-γ-expressing CD4+ T cells were detected in both groups in the absence of antigenic stimuli; however, restimulation with either live M. tuberculosis or ESAT6 increased the frequency of IFN-γ-expressing CD4+ pulmonary T cells of TNFRp75−/− mice (*P < 0.05; Figure 5F). Additionally, we measured IL-10 and IL-13 synthesis as regulators of Th1/Th2 balance (36, 37), where both cytokines can control DC maturation and function (38, 39); however, we found no pulmonary concentration differences between WT and TNFRp75−/− mice during acute or chronic M. tuberculosis infection (Supplemental Figure 3). Thus, our data confirmed that the increased recruitment of activated DCs in TNFRp75−/− mice increases the frequency of activated T cells in LNs, with the capability to generate enhanced M. tuberculosis-specific immune responses.

**TNFRp75 shedding is induced in vivo during M. tuberculosis infection.** Previous studies demonstrated that TNFRp55 and TNFRp75 are shed from the cell surface in response to in vitro virulent M. tuberculosis H37Rv infection (7) or in vivo M. avium infection (6), reducing bioactive TNF. In our studies, flow cytometric analysis of TNFRp75 surface expression in WT DCs revealed a 10-fold reduction in TNFRp75-expressing cells 24 hours after M. tuberculosis infection compared with noninfected cells (P < 0.01; Figure 6A). Detection of TNFRp75 release in culture supernatants of M. tuberculosis-infected WT DCs was assessed to confirm that decreased expression was indeed due to shedding, as opposed to receptor internalization. We observed time-dependent shedding of TNFRp75 in WT DCs, reaching a maximum after 48 hours, and confirmed the absence of TNFRp75 in the TNFRp75−/− cell cultures (Supplemental Figure 4A). Additionally, we compared the kinetics of TNFRp55 shedding in the culture supernatants of M. tuberculosis-infected DCs of WT and TNFRp75−/− mice and found that M. tuberculosis infection induced an increase in TNFRp55 release over 72 hours in both strains (Figure 6B).

To ascertain whether the M. tuberculosis–induced TNFR shedding we observed in vitro also occurs in vivo, we challenged WT, TNFRp55−/−, and TNFRp75−/− mice with M. tuberculosis and assessed TNFRp55 and TNFRp75 levels in bronchoalveolar lavage fluid (BALF) and supernatants of lung homogenates at defined time points. Flow cytometric analysis of bronchoalveolar lavage (BAL) DCs harvested 3 days after infection showed reduced TNFRp75 expression in M. tuberculosis–infected WT versus naive control mice (Figure 6C). We then assessed soluble TNFRp55 and TNFRp75 concentrations in BALF and supernatants of lung homogenates at defined time points to confirm receptor shedding in vivo. We found that TNFRp55 and TNFRp75 were shed subsequent to M. tuberculosis infection and confirmed that TNFRp55 and TNFRp75 were not detectable in TNFRp55−/− and TNFRp75−/− mice, respectively (Figure 6, D and E, and Supplemental Figure 4, A–C). Interestingly, we measured lower TNFRp55 levels in
TNFRp75-/- versus WT mice at all time points, which suggests that TNFRp75 may regulate TNFRp55 shedding. Furthermore, shedding of TNFRp75 was significantly lower in TNFRp55-/- versus WT mice (P < 0.01). These data demonstrated that both TNFRp55 and TNFRp75 are shed during host challenge with M. tuberculosis and that TNFR shedding seems to be regulated by signaling through the opposing TNFR.

Neutralization of TNFRp75 increases DC activation. We hypothesized that TNFRp75 shedding would regulate bioactive TNF concentrations and thus early host immune responses. Therefore, WT and
TNFRp75<sup>−/−</sup> cultured DCs were infected with <i>M. tuberculosis</i> at an MOI of 5:1 in the presence or absence of anti-TNFRp75 and bioactive TNF, and expression of IL-12p40 and MHCII (as indicators of DC activation) was measured. In addition, <i>Tnf</i> mRNA expression, bioactive TNF kinetics, and DC surface TNFRp55 expression were analyzed. Although <i>Tnf</i> mRNA expression was significantly reduced in TNFRp75<sup>−/−</sup> BMDCs (<i>P</i> < 0.05; Figure 7A), bioactive TNF was significantly higher at 4 and 24 hours after infection (<i>P</i> < 0.05 and <i>P</i> < 0.01, respectively; Figure 7B). In addition, we measured and compared pulmonary total TNF and bioactive TNF concentrations in <i>M. tuberculosis</i>–infected WT and TNFRp75<sup>−/−</sup> mice at 1, 3, and 6 days after infection. We found equivalent total TNF concentrations, as opposed to significantly higher bioactive TNF concentrations in TNFRp75<sup>−/−</sup> versus WT mice at 1 and 3 days after infection (<i>P</i> < 0.05; Figure 7, C and D).

We next postulated that the increased bioactive TNF concentrations would have enhanced potential for DC activation via TNFRp55 signaling in the absence of TNFRp75. Flow cytometric analysis revealed upregulation of TNFRp55 in TNFRp75<sup>−/−</sup> BMDCs (Figure 7E). This was strongly supported by analysis of pulmonary DCs showing increased TNFRp55 cell surface expression in <i>M. tuberculosis</i>–infected TNFRp75<sup>−/−</sup> compared with WT mice at 3 days after infection (Figure 7F). TNFRp75-dependent regulation of TNF bioactivity was confirmed in studies where treatment of WT DC cultures with anti-TNFRp75 neutralizing antibody resulted in a bioactive TNF response similar to that of TNFRp75<sup>−/−</sup> DCs (Figure 7G). Thus, these findings reinforced the hypothesis that soluble TNFRp75 inhibits bioactive TNF concentrations. Moreover, we observed increased IL-12p40 production and MHCII expression in <i>M. tuberculosis</i>–infected TNFRp75<sup>−/−</sup> DCs (Figure 7, H and I), confirming enhanced DC activation. Treatment of WT DC cultures with anti-TNFRp75 neutralizing antibody lead to significant increases in IL-12p40 and MHCII expression (<i>P</i> < 0.01 and <i>P</i> < 0.05, respectively; Figure 7, H and I), approaching – albeit not equivalent to – levels of TNFRp75<sup>−/−</sup> DCs. Taken together, these data support a heightened activated phenotype of TNFRp75<sup>−/−</sup> compared with WT DCs after <i>M. tuberculosis</i> infection, mediated by enhanced signaling of bioactive TNF through TNFRp55. Notably, neutralization studies confirmed that the increased immune function potential of DCs was TNFRp75 dependent.

Soluble TNFRp75 inhibition of bioactive TNF regulates Th1-specific immunity. We postulated that improved protection observed in TNFRp75<sup>−/−</sup> mice could either be attributed to (a) loss of signaling though TNFRp75, assuming that TNFRp75–mediated signaling downmodulates protective Th1 immunity, or (b) absent TNFRp75 shedding and the resultant bioactive TNF increase mediating an improved Th1-specific immune response. Previous studies
have demonstrated that TNFRp75 shedding is strain dependent and associated with virulence (7). Therefore, we predicted that TNFRp75 shedding would be less efficient in an attenuated BCG mycobacterial infection model, allowing us to test whether enhanced Th1 immunity in TNFRp75+/− mice is dependent on soluble TNFRp75 and the associated increase in bioactive TNF.

Indeed, we found that BMDCs infected with BCG had TNFRp75 cell surface expression equivalent to that of uninfected BMDCs (Figure 8A). In contrast, BMDCs infected with M. tuberculosis exhibited a reduced TNFRp75 MFI (Figure 8A), indicative of loss of cell surface expression, which confirmed that BCG is less efficient at inducing TNFRp75 shedding. The presence of increased soluble TNFRp75 in BMDC culture supernatants confirmed that the loss of surface expression of TNFRp75 was due to receptor shedding, as opposed to receptor internalization (Figure 8B). Although BCG induced low levels of soluble TNFRp75, concentrations remained significantly reduced compared with those induced by M. tuberculosis (P < 0.05; Figure 8B). More importantly, bioactive TNF concentrations were equivalent in WT and TNFRp75+/− BMDC culture supernatants after BCG challenge, whereas they were significantly increased after virulent M. tuberculosis infection (P < 0.01; Figure 8C). Since WT and TNFRp75+/− DCs produced similar levels of bioactive TNF during BCG challenge, we assessed IL-12p40 production as a measure of cellular activation and found that the increase in IL-12p40 observed in TNFRp75+/− BMDCs during M. tuberculosis infection did not occur during BCG infection, for which receptor shedding was absent. In fact, during BCG infection, WT BMDCs produced significantly increased IL-12p40 compared with TNFRp75+/− BMDCs (P < 0.01; Figure 8D). This suggests that TNFRp75 signaling, rather than being inhibitory, acts in concert with TNFRp55 to induce optimal immune activation.

In order to confirm that soluble TNFRp75 and not membrane-bound TNFRp75 signaling impairs immune responses in WT mice, M. tuberculosis–infected TNFRp75+/− BMDCs were treated with recombinant TNFRp75 so that experimental conditions approximated the TNFRp75 shedding observed in WT mice in the absence of TNFRp75 signaling. Strikingly, we found a dose-dependent reduction of DC activation with increasing exogenous recombinant TNFRp75 administration (Figure 8E). Taken together, these data confirmed that TNFRp75 shedding and the resulting reduction in bioactive TNF, not TNFRp75–mediated signaling effects, downmodulates DC activation and influences disease outcome.

**Discussion**

Although TNF and TNFRp55 are critical for protective immune responses against M. tuberculosis, the role of TNFRp75 was unknown. In the current study, we investigated the effects of TNFRp75, under conditions in which TNFRp55 was either expressed or absent, during M. tuberculosis challenge. Our results demonstrated that soluble TNFRp75 reduces bioactive TNF concentrations, downregulates DC activation, and impairs overall Th1 immune responses, whereas membrane TNFRp75 promotes immune protection.

First, we confirmed that TNFRp55 is critical for survival: both TNFRp55+/− and TNFRp55+/−/TNFRp75+/- mice succumbed to infection, showing increased organ burdens and concomitant weight loss.
both well-documented symptoms of advanced disease. Interestingly, we observed a small but repeatable delay in the death of TNFRp55\(^{+/−}\) compared with TNFRp55/75\(^{+/−}\) mice, suggestive of a possible degree of protection afforded by TNFRp75 in the absence of TNFRp55. Nonetheless, TNFRp55-mediated immune function was nonredundant and could not be rescued by TNFRp75 expression. In contrast, survival during chronic infection was significantly longer in TNFRp75\(^{+/−}\) than WT mice, which suggests that TNFRp75 expression inhibits immune function during M. tuberculosis challenge. TNFRp75-dependent inhibition of host immune function during M. avium challenge was previously reported by Corti et al., who demonstrated immune benefit associated with TNFRp75 neutralization (6). Furthermore, Balicewicz-Sablisna et al. reported that TNFRp75 shedding is an important M. tuberculosis evasion mechanism, particularly in virulent strains (7). Using human alveolar macrophages, the authors found that virulent M. tuberculosis H37Rv bacilli were able to evade apoptosis through IL-10–dependent TNFRp75 shedding, while avirulent M. tuberculosis H37Ra induced less TNFRp75 shedding, reducing efficiency at evading apoptosis. TNFRp75 could form complexes with soluble TNF, thereby reducing TNF bioactivity and subsequent TNF-mediated immune responses (7).

Cellular recruitment is essential for protective immunity against mycobacterial infections (9–11, 13, 27), partly due to its importance in granuloma formation, a critical component in host immunity without which mice die prematurely (11, 30). TNF signaling mediates both cellular recruitment and subsequent granuloma formation in response to mycobacterial infections (11, 13, 27): the absence of TNF impairs formation of structured granulomas, with few epithelial macrophages and significant necrosis (9, 10). TNFRp55 signaling has previously been shown — in both M. tuberculosis (40) and other infection and inflammatory models (41, 42) — to be important for the activation of NF-κB, which results in the synthesis of proinflammatory cytokines, including TNF. Furthermore, as described in the present study and in previous reports (26, 27), TNFRp55 acts as the major conduit of TNF-mediated function, and an inability to signal through TNFRp55 yielded granuloma defects comparable to those observed with TNF deficiency. In both TNFRp55\(^{+/−}\) and TNFRp55/75\(^{+/−}\) mice, structured granulomas were absent and few epithelioid macrophages were noted, despite significantly increased pulmonary cell numbers. In addition, severe necrosis was observed in the absence of TNFRp55-mediated signaling. In contrast, we found that the organization of granulomas in TNFRp75\(^{+/−}\) mice resembled the ordered structure characteristic of WT granulomas. The fewer, smaller granulomas and reduced cell numbers we observed in TNFRp75\(^{+/−}\) mice late in the acute stage of infection could be attributed to a reduced stimulus resulting from a lower bacilli burden in this strain, not an inability to recruit immune cells or form granulomas at the site of infection. In fact, TNFRp75\(^{+/−}\) mice have an enhanced Th1 immune response during early acute infection. Therefore, our findings, together with other reported studies (9, 10), indicate that TNF signaling through TNFRp55 — and not TNFRp75 — is important for granuloma formation.

To understand the immune mechanisms conferring increased protection in TNFRp75\(^{+/−}\) mice, we explored the effects of TNFRp75 on cellular responses during M. tuberculosis infection, with particular emphasis on DCs as an integral component of early defense (43) and an important link between innate and adaptive immunity (44, 45). During early acute infection, TNFRp75\(^{+/−}\) mice presented with an increase in the number of activated CD11c\(^+\) DCs in the lungs, which were characterized by CD80, CD86, and MHCII expression and enhanced IL-12p40 synthesis compared with WT mice. DCs are ideally positioned to contribute to both innate and adaptive immune control. Their role in early innate immune defense has been illustrated by others who found that DCs restrict bacterial replication during early infection (46). It is therefore plausible that early protection in TNFRp75\(^{+/−}\) mice may be associated with enhanced bacterial control related to the increased number of activated DCs in the absence of TNFRp75. The capacity of DCs to establish innate immune control of bacterial infection via TNF/iNOS-dependent mechanisms has previously been reported (47). The potential for superior killing by the increased DC population in the absence of TNFRp75 remains to be defined. In addition to its role in Th1 polarization, DC-derived IL-12 plays a significant role in the migration of DCs to the draining LNs (35), and our present results confirmed that higher IL-12p40 induction mediated an increase in DC migration to draining LNs in M. tuberculosis–infected TNFRp75\(^{+/−}\) mice. T cell activation relies primarily on antigen presentation by DCs in the LN, not the lung, during M. tuberculosis infection (48), and cytokines such as IL-12 are required to induce Th1 polarization (48–50). Enhanced mycobacterial clearance was associated with increased recruitment of M. tuberculosis–specific Th1 cells in the absence of TNFRp75. Interestingly, delayed DC trafficking to LNs hinders timely induction of protective immune responses and alters disease outcome (51). Our results showed enhanced DC migration to LNs in TNFRp75\(^{+/−}\) mice, which suggests that soluble TNFRp75 may delay DC trafficking to LNs and impede optimal induction of T cell–mediated immunity. The increased number of activated DCs and increased IL-12p40 in TNFRp75\(^{+/−}\) mice would therefore suggest favorable conditions in the LN for T cell activation. Indeed, we noted an increased number of activated CD4\(^+\)CD44\(^+\) and CD8\(^+\)CD44\(^+\) T cells in the LNs of TNFRp75\(^{+/−}\) mice. We also confirmed that newly activated T cells were in fact Th1 polarized, capable of producing IFN-γ once recruited to the lungs. Ex vivo restimulation of lung cells from TNFRp75\(^{+/−}\) mice demonstrated an increased ability to generate an M. tuberculosis–specific IFN-γ response to ESAT6 or M. tuberculosis H37Rv compared with WT mice. Therefore, our collective data provide evidence that TNFRp75 regulates the antigen-presenting potential of DCs and the induction of Th1 immune responses during early acute infection.

The clear correlation we demonstrated between increased early Th1 immune responses and control of bacterial replication in TNFRp75\(^{+/−}\) mice emphasizes the importance of a strong early proinflammatory response to the outcome of disease. It also suggests a regulatory role of TNFRp75 in buffering excessive immune function in order to limit immune-mediated tissue damage during M. tuberculosis infection at the expense of achieving early control of bacilli replication, which would ultimately lead to increased host survival. Interestingly, we observed no pathological damage as a result of the increased early proinflammatory response in TNFRp75\(^{+/−}\) mice, which suggests a highly controlled process. Indeed, the early enhanced Th1 response in TNFRp75\(^{+/−}\) mice was downmodulated during later stages of infection, when bacilli replication was controlled, which indicates that the response may be stimuli specific.

In vitro human macrophage studies demonstrated TNFRp55 and TNFRp75 release upon M. tuberculosis infection in which predominantly soluble TNFRp75, rather than soluble TNFRp55, formed complexes with soluble TNF, thereby reducing TNF bioactivity (7). In addition, TNFRp75 cell surface expression and shedding was increased in response to intraperitoneal M. avium
infection (6). Based on the evidence from these studies, we hypothesized that TNFRp55 and TNFRp75 would be released upon M. tuberculosis infection, allowing soluble receptors to bind bioactive TNF and thereby reduce the availability of bioactive TNF for signaling via the membrane-bound receptors. TNF and IFN-γ are known key requirements for optimal cellular activation (52), and reduced availability of bioactive TNF could therefore negatively affect DC activation. Assessment of TNFRp55 and TNFRp75 shedding, both in vivo and in vitro, confirmed the release of TNFRp75 from cell surfaces and demonstrated increased levels of soluble TNFRp75 and TNFRp55 in supernatants after M. tuberculosis infection, in accordance with previous reports (6, 7). Interestingly, the absence of TNFRp75 was associated with significantly lower soluble TNFRp55. Both in vitro and in vivo analysis of TNFRp55 showed increased surface expression in TNFRp75–/– DC cultures or BAL mouse lung cells, which suggests that TNFRp55 shedding is promoted by TNFRp75. In addition, BALF from TNFRp75–/– mice and supernatants from TNFRp75–/– BMDCs had higher concentrations of bioactive TNF, which could potentially all signal through TNFRp55. This indicated that immune responses in TNFRp75–/– mice were characterized by improved TNF-TNFRp55 signaling, which promoted the early Th1 proinflammatory immune response essential for early control of bacilli replication and was accordingly associated with reduced pulmonary pathology. In support of this concept, TNFRp75 neutralization in M. tuberculosis–infected BMDCs increased IL-12p40 and bioactive TNF expression as well as the number of BMDCs expressing MHCI, further indicating that the increased ability of DCs to become activated was due to increased concentrations of bioactive TNF caused by the reduction in soluble TNFR.

Nonetheless, it could be argued that TNF-TNFRp75–mediated signaling inhibits Th1-mediated immunity and that the increased protection observed in TNFRp75–/– mice was the consequence of absent inhibitory signaling through TNFRp75 rather than inhibited bioactive TNF through binding of soluble TNFRp55. To explore this option, we used BCG, an attenuated mycobacterial strain less virulent than M. tuberculosis H37Rv, which allowed for normalization of bioactive TNF concentrations between WT and TNFRp75–/– BMDCs and compared WT and TNFRp75–/– activation after infection. If TNFRp75–mediated signaling was the mechanism of immune inhibition, we would expect decreased activation of WT versus TNFRp75–/– BMDCs when bioactive TNF concentrations were equal. On the contrary, WT BMDCs showed increased activation, which indicated that membrane-bound TNFRp75 may in fact supplement TNFRp55 signaling, as opposed to eliciting an inhibitory effect. We previously reported no difference in disease outcome between WT and TNFRp75–/– mice using BCG (33); based on our present data, this may reflect that TNFRp55 signaling is sufficient to control disease when sufficient bioactive TNF is available. To further confirm that it is soluble TNFRp75 and its ability to decrease bioactive TNF that impedes protection in WT mice, and not TNFRp75–mediated signaling, TNFRp75–/– BMDCs (which have neither membrane-bound nor soluble TNFRp75) were reconstituted with soluble recombinant TNFRp75. The data clearly showed a dose-dependent reduction in DC activation when soluble TNFRp75 was administered to TNFRp75–/– BMDCs, with IL-12p40 concentrations similar to those of WT BMDCs. This argues convincingly in favor of TNFRp75 shedding and consequent reduction in TNF bioavailability as the mechanism of immune regulation during M. tuberculosis infection.

Interestingly, the absence of both TNFRp55 and TNFRp75 resulted in significantly lower IL-12p40 levels than when only TNFRp55 was deleted. The small but repeatable earlier susceptibility of TNFRp55/75–/– versus TNFRp55–/– mice could therefore be due to the small discrepancy in DC activation between the strains.

In summary, our present findings demonstrated that TNFRp75–/– mice present with enhanced protective immunity against aerosol M. tuberculosis infection. Moreover, we clearly demonstrated inhibition of M. tuberculosis–specific Th1 immune responses by soluble TNFRp75 and identified TNF-mediated DC activation as a critical factor determining disease outcome. We have therefore identified TNFRp75 as a viable host-specific target that could potentially be exploited for therapeutic application to improve outcome of disease during M. tuberculosis infection.

Methods

Mice. C57BL/6 WT control, TNFRp55–/– (Tnfrsf1a–/–; ref. 53), and TNFRp75–/– (Tnfrsf1b–/–; ref. 54) mice were obtained from Jackson Laboratories; double-deficient TNFRp55/75–/– mice were generated by mating Tnfrsf1a–/– and Tnfrsf1b–/– mice. All animals were bred and housed in individually ventilated cages under specific pathogen–free conditions in the animal facility of the University of Cape Town. Male and female mice were provided food and water ad libitum and used in experiments at 8–12 weeks of age. Genotypes of the respective mouse strains were confirmed by PCR analysis of tail biopsies.

Antibodies. The following antibodies were used (all from BD Biosciences—Pharmingen): FITC-conjugated rat IgG2a (clone R35-95), PE-conjugated rat IgG2a (clone R35-95), APC-conjugated rat IgG2a (clone R4005), PE-conjugated rat IgG2b (clone R35-95), FITC-conjugated hamster IgG (clone G70-204), PE-conjugated hamster IgG (clone G70-204), PE-conjugated rat anti-mouse CD120b (clone HN102), PE-conjugated anti-mouse CD44 (Pgp-1) (clone IM7), PE-conjugated rat anti-mouse I-A/I-E (clone M5/114.15.2), PE-conjugated hamster anti-mouse CD80 (clone 16-10A1), PE-conjugated rat anti-mouse CD86 (clone GL1), PE-conjugated anti-mouse CD88 (Ly-2) (clone 53-6.7), FITC-conjugated anti-mouse CD8a (Ly-2) (clone 53-6.7), FITC-conjugated hamster anti-mouse CD11c (clone HEL3), FITC-conjugated rat anti-mouse IFN-γ (clone XM1G1.2), APC-conjugated rat anti-mouse CD11b (clone M1/70), APC-conjugated rat anti-mouse CD4 (clone RM4-5), rat anti-mouse CD16/CD32 (clone 2.4G2), anti-mouse CD3e (clone 145-2e11), and anti-mouse CD28 (clone 37.51).

Mycobacteria and infection. M. tuberculosis H37Rv or M. bovis BCG was grown in Difco Middlebrook 7H9 medium containing 0.5% glycerol and enriched with 10% OADC. Cultures were incubated at 37°C and grown until log phase. A frozen aliquot of M. tuberculosis H37Rv was rapidly thawed at 37°C, passed 30 times through a 29.5-gauge needle, and diluted in sterile saline. Mice were infected using a Glas-Col Inhalation Exposure System (model A4224). The pulmonary infection dose was confirmed by sacrificing 10 mice 1 day after infection and plating the homogenized lung tissue on Difco Middlebrook 7H10 agar plates in 10-fold serial dilutions. Plates were semi-sealed in plastic bags and then incubated for 17–21 days at 37°C, after which the number of mycobacterial colonies was counted and the infection dose calculated.

Microscopic analysis. Mice were sacrificed, and organs were fixed in phosphate-buffered formalin. Photographic images were first captured with a Nikon 4500 digital camera and analyzed using Nikon View S software, after which they were embedded in paraffin wax. Tissues were sectioned at 2–3 μm, stained with H&E and Ziehl-Neelsen, and mounted with Canada balsam. Images of stained tissue sections were captured using a Nikon DXM 1200 digital still camera attached to a Nikon Eclipse E400 microscope and ACT-1 software.
Bacterial burden assessment. Mice were killed at defined time points, and mycobacterial burdens in the lungs, liver, and spleen were determined by CFU enumeration. Briefly, organs were homogenized in 1–2 ml sterile saline containing 0.04% Tween 80, and tissue homogenates were plated in 10-fold serial dilution in duplicate on Difco Middlebrooke 7H10 agar (BD). Mycobacterial cultures were semi-sealed in plastic bags and incubated for 18–21 days at 37°C, after which mycobacterial colonies were counted and final organ burdens calculated.

ELISA. Cytokine and soluble receptor sample concentrations were assessed by ELISA as described by the manufacturer. Briefly, infected lungs were removed at the indicated day after infection and homogenized in 1 ml sterile saline containing 0.04% Tween 80. Homogenates were subsequently centrifuged twice at 405 g for 10 minutes at 4°C, and the supernatant was aliquoted and stored at −80°C for further analysis. In addition, culture supernatants from macrophages and DCs were removed, centrifuged twice at 405 g for 10 minutes at 4°C, and then aliquoted and stored at −80°C for further analysis. All ELISA reagents were purchased from R&D Systems, and absorbances were read at 405 nm using a VERSAmax Tunable Microplate Reader (Molecular Devices Corp.). Data were analyzed using SoftMax Pro version 4.3 software (Molecular Devices Corp.).

Bioactive TNF assay. Bioactive TNF was determined using the TNF-sensitive fibroblast cell line WEHI 164, clone 13. An aliquot of WEHI cells was thawed at 37°C and cultured in a 90-mm tissue culture petri dish (Bibby Sterilin) containing 10 ml WEHI Complete medium (RPMI supplemented with 10% FCS, 0.5x amino acid supplement, 10 U/ml penicillin, and 10 μg/ml streptomycin) until confluent. Cells were harvested by trypsin/EDTA and seeded at 2x10^6 cells/well in a 96-well tissue culture plate (Nunclon). Cells were allowed to adhere overnight by incubating at 37°C with 5% CO2. Culture supernatants were removed, centrifuged twice for 10 minutes at 4°C, and the supernatant was aspirated and stored at −80°C for cytokine and soluble TNFR analysis by ELISA. BAL cells were collected by doing 2 lavages each time, using 700 μl sterile PBS. The BAL was aliquoted and stored at −80°C for cytokine and TNFR analysis by ELISA. BAL cells were collected by doing 3 lavages each using 700 μl of 2-mg/ml MTT (Sigma-Aldrich) was added to the samples and incubated at 37°C for 2 hours, after which the supernatant was discarded by aspiration. 50 μl WEHI detection solution (67% propanol, 0.32% HCL, 2 mM g/ml), 50 μl g/ml. For anti-CD3/anti-CD28 stimulation, cells were washed with complete restimulation medium (RPMI supplemented with 5% FCS, 2 mM l-glutamine, 50 μM 2-mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml streptomycin), and red blood cells were lysed in 5 ml/lung red blood cell lysing buffer. Cells were then washed on ice for 1 minute, and 5 ml complete restimulation medium was added prior to centrifugation at 405 RCF at 4°C for 10 minutes. Cells were then either washed in 1x PBS or in complete restimulation medium, or counted for cell staining or restimulation assays. Single-cell suspensions of LNs were prepared by passage through 70-μm cell strainer prior to centrifugation at 405 RCF at 4°C for 10 minutes. Cells were then either washed in 1x PBS or in complete restimulation medium for cell staining or restimulation.

Lung and LN restimulation. 2.2 × 10^6 cells/well were seeded in a 96-well round-bottomed nunc plate (Nunclon). Cells were stimulated with ESAT6 (10 μg/ml), M. tuberculosis at an MOI of 5:1, or anti-CD3/anti-CD28 diluted in complete restimulation medium at 37°C for a total of 6 hours with medium as a control. After the first 2 hours, Brefeldin A (Epitope Bio-technologies) was added to a final concentration of 5 μg/ml. For anti-CD3/anti-CD28 restimulation, wells were coated overnight with anti-CD3/anti-CD28 (5 μg/ml in a volume of 50 μl), and the antibody cocktail was aspirated off prior to the addition of cells. After 6 hours of stimulation, cells were centrifuged for 5 minutes at 514 RCF, resuspended in 220 μl FACS buffer, and replated into 96-well v-bottomed stabilin plates (Bibby Sterilin) for analysis by flow cytometry.

Flow cytometry. BMDCs, or single-cell suspensions of lungs or LNs were labeled in 96-well plates (Bibby Sterilin) with the indicated antibodies. Samples were analyzed on a FACS Calibur (BD) flow cytometer using Cell Quest software (BD). Briefly, 1 × 10^6 BMDCs or BMDCs and 2 × 10^6 lung cells or LN cells were stained with the required antibodies and IgG control antibodies. For intracellular staining, saponin buffer was used to permeabilize the cells. All cells were fixed overnight in 2% paraformaldehyde before analysis.

RNA isolation. Total RNA was isolated from cultured DCs at 4 and 24 hours after M. tuberculosis infection using TriReagent and purified using the RNeasy RNA Extraction kit (Qiagen) according to the manufacturer’s instructions.

Quantitative RT-PCR. cDNA synthesis was performed using the Transcriptor First Strand cDNA Synthesis Kit (Roche), and RT-PCR was performed using the Roche LightCycler 480 SYBR Green 1 Kit (Roche) according to the manufacturer’s instructions. The following primers were used: Tnf forward, 5'-TCTCATTGCTTCTATGGCCC-3'; Tnf reverse, 5'-GGGATTAGCAGATATTACAAC-3'; ribosomal S12 (rS12) for-
ward, 5'-GGAGGCATATTCGCTGAGGAGT-3'; s512 reverse, 5'-CGATTGACATCTTGGCGCTGA-3'. Relative Tnf mRNA expression was calculated by dividing the Tnf value by the s512 (housekeeping gene) value.

Significance. Data are expressed as mean ± SEM. Statistical analysis was performed by ANOVA using GraphPad Prism software (version 4.01). For multiple studies, analysis was performed using the log-rank test. A P value less than 0.05 was considered significant.

Acknowledgments

This study was supported by the National Research Foundation (South Africa), the Medical Research Council (South Africa), University of Cape Town, National Health and Laboratory Services (South Africa), and the European Union (FP6 NEST project no. 028190 “TB REACT”). Research was carried out within the scope of the Franco/South African Laboratory “TB Immunity” (Associated International Laboratory [AIL] no. 236). The authors thank Marylin Tyler for contributing to the histopathology, Natalie Neuwhenhuizen for constructive critique of the manuscript, and the staff of the Division of Immunology and the Animal Unit at UCT for contributing to animal care and technical support.

Received for publication February 22, 2013, and accepted in revised form December 19, 2013.

Address correspondence to: Muazzam Jacobs, Room S1.33, Level 1, Werner Beit South, Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Health Sciences Faculty, University of Cape Town, Anzio Road 7925 Observatory, Cape Town, South Africa. Phone: 27.21.406.6078; Fax: 27.21.406.6078; E-mail: Muazzam.Jacobs@uct.ac.za.